Phosphodiesterase 9A in Brain Regulates cGMP Signaling Independent of Nitric-Oxide

• Published in: Frontiers in neuroscience Vol. 13; p. 837
• Main Authors: Harms, John F, Menniti, Frank S, Schmidt, Christopher J
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Research Foundation 23.08.2019; Frontiers Media S.A
• Subjects: Attention; brain; Brain research; cGMP; Clinical trials; Cognitive ability; Cyclic GMP; Enzymes; Guanylate cyclase; Localization; Mental disorders; Neuroscience; Nitric oxide; Nitric-oxide synthase; PDE9A; Peptides; Phosphodiesterase; phosphodiesterase inhibitor; R&D; Research & development; Schizophrenia; Social research; Therapeutic applications; United States > US; nitric oxide; phosphodiesterase inhibitor; cGMP; nitric oxide synthase; brain; PDE9A; cognitive disorders

PDE9A is a cGMP-specific phosphodiesterase expressed in neurons throughout the brain that has attracted attention as a therapeutic target to treat cognitive disorders. Indeed, PDE9A inhibitors are under evaluation in clinical trials as a treatment for Alzheimer's disease and schizophrenia. Howe...